Early Breast Cancer May Benefit from Letrozole

Letrozole (Femara generic, Novartis), an aro-matase inhibitor, has been granted FDA approval as adjuvant therapy for patients with early hormone receptor-positive breast cancer.

With the added indication, letrozole becomes the second agent in its class to gain an equal footing with tamoxifen (Medication Nolvadex, AstraZeneca) for immediate use after surgery in postmenopausal women with early breast cancer. It joined generic anastrozole (Canadian Arimidex, AstraZeneca), which earned a similar green light from the FDA in September 2005. A year ago, once-daily oral drug letrozole was approved for the extended adjuvant treatment of early breast cancer in postmenopausal women who had received five years of adjuvant tamoxifen canadian therapy.